5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial

• J. Gligorov,
• X. Pivot,
• B. Ataseven,
• M. De Laurentiis,
• A. Llombart,
• K.H. Jung,
• A. Manikhas,
• H.A. Azim,
• A. Alexandrou,
• K. Gupta,
• L. Herraez-Baranda,
• N. Tosti,
• E. Restuccia

Affiliations

J. Gligorov

X. Pivot

B. Ataseven

M. De Laurentiis

A. Llombart

K.H. Jung

A. Manikhas

H.A. Azim

A. Alexandrou

K. Gupta

L. Herraez-Baranda

N. Tosti

E. Restuccia